Entero Healthcare Solutions (NSE:ENTERO) Research & Development: ₹0 Mil (TTM As of Mar. 2026)


NSE:ENTERO Entero Healthcare Solutions Ltd NSE:ENTERO
43 GF Score
Price ₹1,200.10
! 2 Warning Signs
View Full Analysis

What is Entero Healthcare Solutions Research & Development?

Entero Healthcare Solutions NSE:ENTERO +1.67% 43 Research & Development is ₹0 Mil as of Mar. 2026. GuruFocus rates NSE:ENTERO with a GF Score™ of 43/100. The stock has 2 warning signs investors should review.

Research & Development is the aggregate amount of research and development expenses during the year. Entero Healthcare Solutions's Research & Development for the three months ended in Mar. 2026 was ₹0 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Mar. 2026 was ₹0 Mil.

Entero Healthcare Solutions  (NSE:ENTERO) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

Entero Healthcare Solutions Research & Development Related Terms

Entero Healthcare Solutions Research & Development Historical Data

* Premium members only.

The historical data trend for Entero Healthcare Solutions's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Entero Healthcare Solutions Research & Development Chart

Entero Healthcare Solutions Annual Data
Trend Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Research & Development
Get a 7-Day Free Trial 0.00 0.00 0.00 0.00 0.00

Entero Healthcare Solutions Quarterly Data
Mar21 Mar22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Research & Development Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
NSE:ENTERO
43GF Score
Entero Healthcare Solutions Ltd NSE:ENTERO
Research & Development is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Entero Healthcare Solutions Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ₹0 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Research & Development →
What does a Research & Development of ₹0 Mil mean?
Entero Healthcare Solutions (NSE:ENTERO) has a Research & Development of ₹0 Mil as of Mar. 2026. Research and development expense is the total cost for research and development activities. View historical data on Entero Healthcare Solutions and its competitors.
Is Entero Healthcare Solutions' Research & Development too high?
Entero Healthcare Solutions' current Research & Development is ₹0 Mil. Overall, Entero Healthcare Solutions has a GF Score™ of 43/100, reflecting its overall financial health beyond just this single metric.
How does Entero Healthcare Solutions' Research & Development compare to MCK and CAH?
Entero Healthcare Solutions' Research & Development of ₹0 Mil can be compared against companies in the Medical Distribution industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Research & Development for a Medical Distribution company?
A good Research & Development depends on the Medical Distribution industry context. However, Research & Development should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Research & Development mean?
A high Research & Development can signal that a stock is expensive relative to its fundamentals. Research and development expense is the total cost for research and development activities. View historical data on Entero Healthcare Solutions and its competitors. Entero Healthcare Solutions's current Research & Development is ₹0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Entero Healthcare Solutions stock overvalued right now?
Entero Healthcare Solutions (NSE:ENTERO) has a current Research & Development of ₹0 Mil. The current Research & Development is ₹0 Mil. Entero Healthcare Solutions' overall GF Score™ is 43/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Research & Development calculated?
Research & Development is calculated from a company's financial statements. For Entero Healthcare Solutions (NSE:ENTERO), the current Research & Development is ₹0 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Entero Healthcare Solutions Business Description

Other Exchanges 544122:India
Address Bandra Kurla Complex, Trade Centre, Unit No. 605 & 606, 6th Floor, Bandra East, Mumbai, MH, IND, 400051
Entero Healthcare Solutions Ltd is a healthcare products distributor in India. It is involved in the business of distribution and marketing of pharmaceutical and surgical products and allied services. Geographically, the company derives a majority of its revenue from the domestic market.
43GF Score

Get the complete analysis for NSE:ENTERO

Research & Development is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹1,200.10
Price